In summary, using complementary methods, including ExCITE-seq and functional flow cytometry assays, we established that DRP-104 not only targets tumor-intrinsic purine metabolism but also diminishes Tregs and exhausted T cell populations that characterize Keap1 mutant lung tumors. This evidence concerns the gene KEAP1 and neoplasm.